A Thermostable mRNA Vaccine against COVID-19 | Zendy

Na-Na Zhang | Zendy; Xiao-Feng Li | Zendy; YongQiang Deng | Zendy; Hui Zhao | Zendy; Yi-Jiao Huang | Zendy; Guan Yang | Zendy; Weijin Huang | Zendy; Peng Gao | Zendy; Chao Zhou | Zendy; Rong-Rong Zhang | Zendy; Yan Guo | Zendy; Shi-Hui Sun | Zendy; Hang Fan | Zendy; Shu-Long Zu | Zendy; Qi Chen | Zendy; Qi He | Zendy; Tian-Shu Cao | Zendy; XingYao Huang | Zendy; Hong-Ying Qiu | Zendy; Jian-Hui Nie | Zendy; Yuhang Jiang | Zendy; Hua-Yuan Yan | Zendy; Qing Ye | Zendy; Xia Zhong | Zendy; Xia-Lin Xue | Zendy; Zhen-Yu Zha | Zendy; Dongsheng Zhou | Zendy; Xiao Yang | Zendy; You-Chun Wang | Zendy; Bo Ying | Zendy; ChengFeng Qin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Thermostable mRNA Vaccine against COVID-19

Author(s) -

Na-Na Zhang,

Xiao-Feng Li,

YongQiang Deng,

Hui Zhao,

Yi-Jiao Huang,

Guan Yang,

Weijin Huang,

Peng Gao,

Chao Zhou,

Rong-Rong Zhang,

Yan Guo,

Shi-Hui Sun,

Hang Fan,

Shu-Long Zu,

Qi Chen,

Qi He,

Tian-Shu Cao,

XingYao Huang,

Hong-Ying Qiu,

Jian-Hui Nie,

Yuhang Jiang,

Hua-Yuan Yan,

Qing Ye,

Xia Zhong,

Xia-Lin Xue,

Zhen-Yu Zha,

Dongsheng Zhou,

Xiao Yang,

You-Chun Wang,

Bo Ying,

ChengFeng Qin

Publication year - 2020

Publication title -

cell

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 26.304

H-Index - 776

eISSN - 1097-4172

pISSN - 0092-8674

DOI - 10.1016/j.cell.2020.07.024

Subject(s) - biology , covid-19 , virology , messenger rna , computational biology , genetics , gene , infectious disease (medical specialty) , outbreak , medicine , disease , pathology

There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research